Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology
Immune checkpoint inhibitors (ICI) are being increasingly used to successfully treat several types of cancer. However, due to their mode of action, these treatments are associated with several immune-related adverse events (irAEs), including immune-mediated autoimmune-like hepatitis in 5 to 10% of c...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.907591/full |
| _version_ | 1811329971700891648 |
|---|---|
| author | Julian Hercun Julian Hercun Catherine Vincent Catherine Vincent Marc Bilodeau Marc Bilodeau Pascal Lapierre Pascal Lapierre |
| author_facet | Julian Hercun Julian Hercun Catherine Vincent Catherine Vincent Marc Bilodeau Marc Bilodeau Pascal Lapierre Pascal Lapierre |
| author_sort | Julian Hercun |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICI) are being increasingly used to successfully treat several types of cancer. However, due to their mode of action, these treatments are associated with several immune-related adverse events (irAEs), including immune-mediated autoimmune-like hepatitis in 5 to 10% of cases. The specific immune mechanism responsible for the development of immune-mediated liver injury caused by immune checkpoint inhibitors (ILICI) is currently unknown. This review summarizes the current knowledge on hepatic irAEs during cancer immunotherapy. It also addresses the clinical management of ILICI and how it is becoming an increasingly important clinical issue. Clinical, histological, and laboratory features of autoimmune hepatitis (AIH) and ILICI are compared, and their shared and distinctive traits are discussed in an effort to better understand the development of hepatic irAEs. Finally, based on the current knowledge of liver immunology and AIH pathogenesis, we propose a series of events that could trigger the observed liver injury in ICI-treated patients. This model could be useful in the design of future studies aiming to identify the specific immune mechanism(s) at play in ILICI and improve immune checkpoint inhibitor cancer immunotherapy. |
| first_indexed | 2024-04-13T15:54:15Z |
| format | Article |
| id | doaj.art-8b56b640bef449aaabf790b87002831c |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-13T15:54:15Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-8b56b640bef449aaabf790b87002831c2022-12-22T02:40:46ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-06-011310.3389/fimmu.2022.907591907591Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver ImmunologyJulian Hercun0Julian Hercun1Catherine Vincent2Catherine Vincent3Marc Bilodeau4Marc Bilodeau5Pascal Lapierre6Pascal Lapierre7Département de médecine, Université de Montréal, Montréal, QC, CanadaCentre de recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Université de Montréal, Montréal, QC, CanadaDépartement de médecine, Université de Montréal, Montréal, QC, CanadaCentre de recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Université de Montréal, Montréal, QC, CanadaDépartement de médecine, Université de Montréal, Montréal, QC, CanadaCentre de recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Université de Montréal, Montréal, QC, CanadaDépartement de médecine, Université de Montréal, Montréal, QC, CanadaCentre de recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Université de Montréal, Montréal, QC, CanadaImmune checkpoint inhibitors (ICI) are being increasingly used to successfully treat several types of cancer. However, due to their mode of action, these treatments are associated with several immune-related adverse events (irAEs), including immune-mediated autoimmune-like hepatitis in 5 to 10% of cases. The specific immune mechanism responsible for the development of immune-mediated liver injury caused by immune checkpoint inhibitors (ILICI) is currently unknown. This review summarizes the current knowledge on hepatic irAEs during cancer immunotherapy. It also addresses the clinical management of ILICI and how it is becoming an increasingly important clinical issue. Clinical, histological, and laboratory features of autoimmune hepatitis (AIH) and ILICI are compared, and their shared and distinctive traits are discussed in an effort to better understand the development of hepatic irAEs. Finally, based on the current knowledge of liver immunology and AIH pathogenesis, we propose a series of events that could trigger the observed liver injury in ICI-treated patients. This model could be useful in the design of future studies aiming to identify the specific immune mechanism(s) at play in ILICI and improve immune checkpoint inhibitor cancer immunotherapy.https://www.frontiersin.org/articles/10.3389/fimmu.2022.907591/fullimmunotherapycancerhepatitisimmune-related adverse eventliver |
| spellingShingle | Julian Hercun Julian Hercun Catherine Vincent Catherine Vincent Marc Bilodeau Marc Bilodeau Pascal Lapierre Pascal Lapierre Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology Frontiers in Immunology immunotherapy cancer hepatitis immune-related adverse event liver |
| title | Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology |
| title_full | Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology |
| title_fullStr | Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology |
| title_full_unstemmed | Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology |
| title_short | Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology |
| title_sort | immune mediated hepatitis during immune checkpoint inhibitor cancer immunotherapy lessons from autoimmune hepatitis and liver immunology |
| topic | immunotherapy cancer hepatitis immune-related adverse event liver |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.907591/full |
| work_keys_str_mv | AT julianhercun immunemediatedhepatitisduringimmunecheckpointinhibitorcancerimmunotherapylessonsfromautoimmunehepatitisandliverimmunology AT julianhercun immunemediatedhepatitisduringimmunecheckpointinhibitorcancerimmunotherapylessonsfromautoimmunehepatitisandliverimmunology AT catherinevincent immunemediatedhepatitisduringimmunecheckpointinhibitorcancerimmunotherapylessonsfromautoimmunehepatitisandliverimmunology AT catherinevincent immunemediatedhepatitisduringimmunecheckpointinhibitorcancerimmunotherapylessonsfromautoimmunehepatitisandliverimmunology AT marcbilodeau immunemediatedhepatitisduringimmunecheckpointinhibitorcancerimmunotherapylessonsfromautoimmunehepatitisandliverimmunology AT marcbilodeau immunemediatedhepatitisduringimmunecheckpointinhibitorcancerimmunotherapylessonsfromautoimmunehepatitisandliverimmunology AT pascallapierre immunemediatedhepatitisduringimmunecheckpointinhibitorcancerimmunotherapylessonsfromautoimmunehepatitisandliverimmunology AT pascallapierre immunemediatedhepatitisduringimmunecheckpointinhibitorcancerimmunotherapylessonsfromautoimmunehepatitisandliverimmunology |